Evotec (EVO)

Executive Summary

Evotec is a Hamburg-based biotechnology company that integrates contract research organization (CRO) services with proprietary AI-driven drug discovery platforms. The company serves all Top 20 pharmaceutical firms and over 800 biotech companies globally, generating recurring revenue through partnerships and platform licenses. Its Just-Evotec Biologics division has pioneered continuous bioprocessing for biologics manufacturing, positioning the company at the forefront of next-generation biotherapeutics. Evotec's business model reduces dependence on its own pipeline, but the company also advances a small portfolio of internal assets. The recent Phase 1 trial for a plague prophylaxis antibody (JST-010) represents one of the few active clinical-stage programs. Financially, Evotec has a market cap of approximately $1.1 billion and is publicly traded (EVO). The company's near-term growth hinges on expanding its partnership network, advancing its AI capabilities, and achieving milestones in biologics manufacturing. While the pipeline is limited, Evotec's service-based revenue provides a stable foundation, and the stock is valued for its exposure to the broader drug discovery ecosystem.

Upcoming Catalysts (preview)

• Q3 2026Q3 2026 Earnings Report100% success
• 2026Major Partnership Deal with Top Pharma for AI Drug Discovery40% success
• 2026Update on Just-Evotec Biologics Capacity Expansion or Platform Milestone30% success